The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC.
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy [Recensione] / P. Grassi, E. Verzoni, R. Ratta, A. Mennitto, F. de Braud, G. Procopio. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - 10(2016), pp. 2167-2172. [10.2147/DDDT.S104225]
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy
E. VerzoniSecondo
;A. Mennitto;F. de BraudPenultimo
;
2016
Abstract
The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC.File | Dimensione | Formato | |
---|---|---|---|
DDDT-104225-cabozantinib-in-the-treatment-of-advanced-renal-cell-carcino_070516.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
201.64 kB
Formato
Adobe PDF
|
201.64 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.